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Summary
Background Whether the addition of radiation therapy (RT) improves overall survival in men with locally advanced 
prostate cancer  managed with androgen deprivation therapy (ADT) is unclear. Our aim was to compare outcomes in 
such patients with locally advanced prostate cancer.
Methods Patients with: locally advanced (T3 or T4) prostate cancer (n=1057); or organ-conﬁ ned disease (T2) with either 
a prostate-speciﬁ c antigen (PSA) concentration more than 40 ng/mL (n=119) or PSA concentration more than 20 ng/mL 
and a Gleason score of 8 or higher (n=25), were randomly assigned (done centrally with stratiﬁ cation and dynamic 
minimisation, not masked) to receive lifelong ADT and RT (65–69 Gy to the prostate and seminal vesicles, 45 Gy to the 
pelvic nodes). The primary endpoint was overall survival. The results presented here are of an interim analysis planned 
for when two-thirds of the events for the ﬁ nal analysis were recorded. All eﬃ  cacy analyses were done by intention to 
treat and were based on data from all patients. This trial is registered at controlledtrials.com as ISRCTN24991896 and 
Clinicaltrials.gov as NCT00002633.
Results Between 1995 and 2005, 1205 patients were randomly assigned (602 in the ADT only group and 603 in the 
ADT and RT group); median follow-up was 6·0 years (IQR 4·4–8·0). At the time of analysis, a total of 320 patients 
had died, 175 in the ADT only group and 145 in the ADT and RT group. The addition of RT to ADT improved overall 
survival at 7 years (74%, 95% CI 70–78 vs 66%, 60–70; hazard ratio [HR] 0·77, 95% CI 0·61–0·98, p=0·033). Both 
toxicity and health-related quality-of-life results showed a small eﬀ ect of RT on late gastrointestinal toxicity (rectal 
bleeding grade >3, three patients (0·5%) in the ADT only group, two (0·3%) in the ADT and RT group; diarrhoea 
grade >3, four patients (0·7%) vs eight (1·3%); urinary toxicity grade >3, 14 patients (2·3%) in both groups).
Interpretation The beneﬁ ts of combined modality treatment—ADT and RT—should be discussed with all patients 
with locally advanced prostate cancer.
Funding Canadian Cancer Society Research Institute, US National Cancer Institute, and UK Medical Research Council. 
Introduction
913 000 new cases of prostate cancer and 215 000 deaths 
occurred worldwide in 2008.1 In the USA prostate cancer 
is the most frequently diagnosed cancer in men and is 
second only to lung cancer as a cause of cancer deaths.2 
The proportion of patients presenting with locally 
advanced disease (at stages T3 or T4) at diagnosis has 
decreased in the past 20 years, largely as a result of 
widespread prostate-speciﬁ c antigen (PSA) screening.3 
However, locally advanced disease is still a common 
clinical challenge and its management controversial.4
In a randomised trial of patients with locally advanced 
disease,5 comparing orchiectomy alone, radiation therapy 
(RT) alone, and combined RT and orchiectomy, no 
diﬀ erences in survival between the three groups was 
recorded. However, this study had poor accrual and the 
number of patients randomised was not suﬃ  cient to 
detect clinically relevant survival diﬀ erences. Data that 
emerged in the early 1990s suggest that adjuvant androgen 
deprivation therapy (ADT) improves outcomes compared 
with RT alone. However, in view of the adoption of early 
ADT for management of patients with locally advanced 
disease, the beneﬁ t of RT is still uncertain. Our aim was 
to assess the role of local RT in addition to ADT in patients 
with locally advanced prostate cancer.
Methods
Participants
The NCIC Clinical Trials Group (NCIC CTG) PR.3/
Medical Research Council (MRC) UK PR07 trial was an 
unmasked, randomised trial done in collaboration with 
the Eastern Cooperative Oncology Group and the 
Southwest Oncology Group. At the study’s initiation 
in 1995, the criteria for participation in the trial were 
histologically conﬁ rmed prostate adenocarcinoma with 
locally advanced disease (clinical tumour stage T3 or T4, 
N0 or NX, or M0 disease). In 1999, the entry criteria were 
broadened to include patients with clinical T2 tumours 
with either PSA concentration of more than 40 ng/mL or 
both T2 and PSA concentration of more than 20 ng/mL 
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with a Gleason score of more than 8. Additional criteria 
were an Eastern Cooperative Oncology Group 
performance status of 0–2, and age less than 80 years. 
Pelvic lymph nodes were not imaged unless the planned 
radiation area was to the prostate only and was negative 
for nodal involvement. Surgical staging was allowed, but 
if done pelvic nodes had to be histologically conﬁ rmed 
free of disease. Previous treatment for prostate cancer 
was not allowed, with the exception of neoadjuvant ADT 
in the 12 weeks before randomisation. No central 
histological review was done. The appropriate national 
and local regulatory and ethical approvals were obtained, 
and all patients provided written informed consent.
Randomisation and masking
All randomisation was done centrally by computer with 
stratiﬁ cation by dynamic minimisation. Patients were 
randomly assigned to receive ADT only, or ADT and RT. 
Patients were stratiﬁ ed by institution, PSA concentration 
at diagnosis, type of ADT (orchiectomy or luteinising 
hormone-releasing hormone [LHRH] agonist), neo-
adjuvant ADT, lymph node staging, and Gleason score.6 
Participating North American centres were randomly 
assigned to use one of the two quality-of-life instruments, 
either the European Organisation for Research and 
Treatment of Cancer (EORTC) QLQ-C30 (version 3) 
with the PR13 prostate-speciﬁ c module, or Functional 
Assessment of Cancer Therapy–Prostate (FACT-P).7,8 All 
participating MRC UK centres used FACT-P. Patients 
and investigators were not masked.
Procedures
All patients received lifelong ADT before randomisation; 
patients chose between bilateral orchiectomy or LHRH 
agonist (initially given with 2 weeks of antiandrogens, 
which could be continued at the investigator’s discretion). 
RT was started within 8 weeks of randomisation and 
delivered with a four-ﬁ eld box technique. The pelvic 
target volume (45 Gy given in 25 fractions over 5 weeks) 
included the whole pelvis, the prostate, seminal vesicles, 
and external and internal iliac lymph nodes. The prostate 
target volume (20–24 Gy given in 10–12 fractions 
over 2–2·5 weeks, at the investigator’s discretion) 
encompassed the prostate gland with known periprostatic 
tumour extension. The dose was speciﬁ ed at the 
intersection of the beam axes according to  International 
Commission on Radiation Units guidelines.9 Patients 
with histologically negative lymph nodes and those for 
whom the treating physician judged that pelvic RT was 
inappropriate were treated to the prostate volume 
(65–69 Gy).
The trial’s primary outcome measure of overall survival 
was deﬁ ned as survival from time of randomisation to 
date of death from any cause or censored at the date of 
last follow-up. The secondary outcome measures were 
disease-speciﬁ c survival, time to disease progression, 
symptomatic local control measured by the rates of 
surgical interventions necessary for symptomatic local 
disease, and health-related quality of life (HRQoL). 
Toxicity was reported with the the National Cancer 
Institute of Canada Clinical Trials Group expanded 
common toxicity criteria.
Cause of death was deﬁ ned by the investigator. Disease 
progression was deﬁ ned as the ﬁ rst of: biochemical 
relapse, local progression, distant metastatic spread, or 
death from prostate cancer. Biochemical relapse was 
deﬁ ned as a PSA concentration of more than 10 ng/mL in 
two consecutive samples if a minimum PSA concentration 
of less than 4 ng/mL was reached at any time, or if serum 
PSA was never less than 4 ng/mL, a PSA concentration of 
both more than 10 ng/mL and 20% higher than the 
minimum value. Local progression was deﬁ ned as either 
ureteral obstruction or progressive disease accompanied 
by a biopsy sample showing tumour. Distant metastases 
were assessed by routine imaging.
Statistical analysis
The original design assumed a 10-year survival of 35% for 
patients with T3, N0, M0 prostate cancer treated with 
ADT-only. To detect a 10% improvement in 10-year survival 
(with a hazard ratio [HR] of 0·76), with 80% power by a 
one-sided 5% threshold test, a sample size of 650 eligible 
patients was needed. In September, 2002, after 688 patients 
had been recruited, only 46 events (deaths) were reported. 
The trial design was then amended to assume a 10-year 
survival of 57% in the ADT-only group (on the basis of 
data from the EORTC 22863 study10), with the same target 
HR and power. The primary test was changed to have a 
two-sided 5% signiﬁ cance threshold, and the sample size 
was increased to 1200 patients.11 After adjustment for two 
planned interim analyses, a minimum of 421 events was 
calculated to be needed for the ﬁ nal analysis.
Eligible patients with 
locally advanced disease
603 allocated ADT and RT 602 allocated ADT alone
586 received RT 
72% RT to pelvis and prostate
603 included in analysis
145 dead
602 included in analysis
175 dead
5 ineligible
1 hormone started 17 weeks 
pre-randomisation
2 staging criteria not met
2 other primary before
randomisation 
3 ineligible
2 other primary before
randomisation
1 previous prostate cancer
9 received RT
Figure 1: Trial proﬁ le
ADT=androgen deprivation therapy. RT=radiation therapy.
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Overall survival was assessed with the Kaplan-Meier 
product limit method and compared with a log-rank 
test stratiﬁ ed by the minimising factors at random-
isation. HRs and CIs were estimated with the Cox 
model. Event rates were calculated with Kaplan-Meier 
or cumulative incidence estimates. The Gray test12  was 
used to test the diﬀ erence in the cumulative cause-
speciﬁ c incidences. All eﬃ  cacy analyses were done by 
intention to treat and used data from all patients. 
SAS software (version 9.1) was used for the statis-
tical analyses.
Two interim analyses were prospectively planned for 
when a third and two-thirds of the events for the ﬁ nal 
analysis were recorded. The ﬁ rst interim analysis was 
done in March, 2006, with a stopping guideline p value 
of 0·001 or less. The data safety monitoring committee 
(DSMC) reviewed the results and recommended that the 
study continue. The second interim analysis was done in 
August, 2009, with 320 deaths, with a stopping guideline 
p value of less than 0·02 based on the Lan-Demets error 
spending function with O’Brien-Fleming-type bound-
aries.13 The DSMC reviewed the data and noted that 
although the results did not meet the protocol criteria 
for early discontinuation on the basis of the test of 
signiﬁ cance, an eﬀ ect was present, which was consistent 
with the previous interim analysis in the subgroups for 
overall survival and with other eﬃ  cacy endpoints (time 
to progression and disease-speciﬁ c survival), as well as 
with the results of a phase 3 trial of similar design.14 On 
the basis of these observations, the DSMC recommended 
external disclosure of the study results. The results of 
the second interim analysis form the basis of this report. 
The protocol-speciﬁ ed ﬁ nal analysis is planned for when 
at least 421 deaths are reported.
HRQoL questionnaires were scored according to 
EORTC (core questionnaire and PR13 prostate-cancer 
module) and Functional Assessment of Chronic Illness 
Therapy standards.7,15 For this interim analysis, the 
HRQoL analysis focused on the hypothesis that 
treatment groups would diﬀ er in mean HRQoL scores 
for measures relevant to pelvic RT, tested by comparing 
mean score change from baseline without adjustment 
for missing data.16 A mean score change of 7 (FACT-P) 
or 10 (EORTC) was judged clinically important.15,16 The 
trial statistician was masked to what treatment the 
patients received.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
This trial is registered at controlledtrials.com 
as ISRCTN24991896 and Clinicaltrials.gov as 
NCT00002633.
Results
Between March, 1995, and August, 2005, 1205 patients 
entered the study and were randomly assigned to 
receive ADT only or ADT and RT (ﬁ gure 1). At the time 
Androgen deprivation 
therapy (n=602) 
Androgen deprivation 
therapy and radiation 
therapy (n=603)
Patient characteristics
Region of recruitment
North America 180 (30%) 181 (30%)
UK 422 (70%) 422 (70%)
Prostate-speciﬁ c antigen 
<20 ng/mL 224 (37%) 220 (36%)
20–50 ng/mL 228 (38%) 228 (38%)
>50 ng/mL 150 (25%) 155 (26%)
Median (IQR) 28 (13·9–49·8) 27 (14·1–51·3)
Gleason score
Not available 6 (1%) 3 (<1%)
<8 489 (81%) 489 (81%)
8–10 107 (18%) 111 (18%)
Previous hormone therapy
No 347 (58%) 347 (58%)
Yes 255 (42%) 256 (42%)
Age at allocation 
<65 years 134 (22%) 132 (22%)
≥65 years 468 (78%) 471 (78%)
Median (IQR) 69·7 (65·5–73·5) 69·7 (65·5–74·0)
Performance status (ECOG)
0 474 (79%) 469 (78%)
1 119 (20%) 126 (21%)
2 9 (1%) 8 (1%)
Clinical stage
Missing 0 (0%) 2 (<1%)
T2 76 (13%) 70 (12%)
T3 499 (83%) 501 (83%)
T4 27 (4%) 30 (5%)
Lymph node staging
Clinical or radiological 477 (79%) 475 (79%)
Not done 113 (19%) 111 (18%)
Surgical 12 (2%) 17 (3%)
Health-related quality-of-life scores
FACT-P, global assessment* (n=844) 55·3 (1·4) 58·1 (1·4)
EORTC, global assessment* (n=179) 77·8 (1·9) 77·4 (1·9)
FACT-P, physical function* (n=844) 90·7 (0·5) 90·3 (0·6)
EORTC, physical function* (n=179) 92·5 (1·2) 91·4 (1·7)
EORTC, bowel or rectum† (n=179) 3·6 (1·2) 3·3 (0·9)
EORTC, diarrhoea† (n=179) 4·3 (1·1) 5·8 (1·9)
EORTC, urinary† (n=180) 9·7 (1·7) 11·2 (1·7)
FACT-P, urinary† (n=835) 28·8 (1·4) 29·7 (1·4)
Data are n (%) or mean (SE). EORTC=European Organisation for Research and Treatment of Cancer, quality-of-life 
questionnaire and the PR-13 prostate module. *High scores represent a high quality of life. †High scores represent a high 
symptom burden. FACT-P=Functional Assessment of Cancer Therapy–Prostate Module. 
Table 1: Patients’ baseline characteristics at study entry
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of analysis (data cutoﬀ  Dec 31, 2008) the median follow-
up from randomisation was 6·0 years (IQR 4·4–8·0), 
with a maximum of 13·3 years. Because of the interim 
nature of this analysis, 103 patients were incompletely 
followed up for at least 2 years (42 participants in the 
ADT only group, 61 participants in the ADT and 
RT group).
Table 1 shows the baseline characteristics of the 
patients. Of the 603 patients randomised to receive ADT 
and RT, 13 did not receive RT, and data are unavailable 
for four; 560 (96%) received 64–69 Gy, 17 (3%) received 
less than 64 Gy, and 12 (2%) received more than 69 Gy. 
419 (72%) of patients received RT to the prostate and 
pelvic lymph nodes and 167 (28%) were treated to the 
prostate alone. Nine patients randomised to ADT only 
received RT as part of their initial management (deﬁ ned 
as RT more than 50 Gy to the prostate and pelvis given 
within 1 year of randomisation with no evidence of 
relapse). LHRH agonists were used as ADT in 
1105 patients (92%), and orchiectomy was done in 93 (8%), 
Number at risk
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Survival at 7 years (95% CI)
ADT: 66% (60–70)
ADT and RT: 74% (70–78)
Log-rank p=0·03
ADT
ADT and RT
Survival at 7 years (95% CI)
ADT: 79% (64–83)
ADT and RT: 90% (86–93)
Log-rank p=0·0001
ADT
ADT and RT
Death related to disease
ADT
ADT and RT
Death not related to disease
Death related to disease
Log-rank p=0·001
Gray p=0·001
7 years ADT: 0·19
7 years ADT and RT: 0·09
Death not related to disease
Log-rank p=0·996
Gray p=0·734
7 years ADT: 0·16
7 years ADT and RT: 0·17
Figure 2: Overall and disease-speciﬁ c survival at 7 years
(A) Kaplan-Meier curve for overall survival by treatment group. (B) Kaplan-Meier 
curve for disease-speciﬁ c survival by treatment group, and (C) cumulative 
incidence of disease-speciﬁ c survival. ADT=androgen deprivation therapy. 
RT=radiation therapy.
Androgen 
deprivation 
therapy 
alone 
(n=602)
Androgen 
deprivation 
therapy and 
radiation 
therapy 
(n=603)
p 
value
Reported by toxicity criteria
Gastrointestinal
Diarrhoea (grade 1–2) 47 (8%) 81 (13%) ··
Diarrhoea (grade >3) 4 (<1%) 8 (1%) ··
Rectal bleeding (grade 1–2) 30 (5%) 75 (12%) ··
Rectal bleeding (grade >3) 3 (1%) 2 (<1%) ··
Genitourinary (grade 1–2) 252 (2%) 262 (43%) ··
Genitourinary (grade >3) 14 (2%) 14 (2%) ··
By patient-reported outcomes
Overall score
FACT-P* (at 6 months; n=716) 4·3 (1·5) –3·0 (1·6) 0·002
FACT-P* (at 36 months; n=538) 2·5 (2·0) –1·1 (1·8) 0·2 
EORTC* (at 6 months; n=148) –1·74 (1·7) –8·98 (2·5) 0·04
EORTC* (at 36 months; n=123) –9·4 (2·1) –11·4 (2·4) 0·96
Physical functioning
FACT-P* (at 6 months; n=721) –4·1 (0·7) –7·6 (0·7) 0·01
FACT-P* (at 36 months; n=545) –6·1 (0·8) –5·5 (0·8) 0·74
EORTC* (at 6 months; n=151) –3·5 (1·7) –3·8 (1·7) 0·72
EORTC* (at 36 months; n=124) –9·2 (2·3) –10·2 (2·4) 0·67
Urinary functioning
FACT-P* (at 6 months; n=706) –6·1 (1·2) 0·1 (1·2) 0·003
FACT-P* (at 36 months; n=528) –5·2 (1·3) –5·5 (1·3) 0·74
EORTC* (at 6 months; n=149) –1·4 (1·3) 0·1 (1·3) 0·07
EORTC* (at 36 months; n=124) –0·6 (1·4) –0·4 (1·4) 0·72
Bowel or rectal
EORTC† (at 6 months; n=149) –1·3 (0·8) 3·4 (1·7) 0·02
EORTC† (at 36 months; n=121) –0·3 (1·3) 1·7 (2·0) 0·54
Diarrhoea
EORTC† (at 6 months; n=149) –1·8 (1·4) 7·3 (2·5) 0·001
EORTC† (at 36 months; n=120) 1·1 (2·2) 1·7 (2·4) 0·33 
Data are n (%) or mean (SE), unless otherwise stated. *Negative scores represent 
worse function compared with baseline. †Positive scores represent reduced 
symptom burden compared with baseline. FACT-P=Functional Assessment of 
Cancer Therapy–Prostate Module. EORTC=European Organisation for Research and 
Treatment of Cancer, quality-of-life questionnaire, and the PR-13 prostate module.
Table 2: Late eﬀ ects of treatment
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with much the same numbers in both treatment groups 
(555 vs 45 in the ADT group, and 550 vs 48 in the ADT 
and RT group).
At the time of this analysis, a total of 320 patients had 
died, 175 in the ADT only group and 145 in the ADT and 
RT group (ﬁ gure 2). The addition of radiation to ADT 
resulted in signiﬁ cantly improved survival (HR 0·77, 
95% CI 0·61–0·98, p=0·03). Overall survival at 7 years was 
74% (95% CI 70–78) in the ADT plus RT group compared 
with 66% (60–70) in the ADT only group (ﬁ gure 2).
Prostate cancer was the cause of death in 140 patients 
(44%), 89 (51%) in the ADT only group and 51 (35%) in 
ADT and RT group. The addition of radiation to ADT 
reduced the risk of death from prostate cancer (HR 0·54, 
0·27–0·78, p=0·0001; ﬁ gure 2). The 7-year cumulative 
disease-speciﬁ c deaths were 9% for patients receiving 
ADT and RT, and 19% for patients receiving ADT only 
(p=0·001; Gray test; ﬁ gure 2). The incidence of death 
from other causes did not diﬀ er signiﬁ cantly between 
groups (ﬁ gure 2; p=0·734).
A total of 346 patients developed progressive 
disease—251 in the ADT only group and 95 in the ADT 
and RT group. The median time to progression in the 
ADT only group was 6·8 years (IQR 3·4–not reached) 
and not reached (IQR 8·2–not reached) in the ADT and 
RT group (estimated HR 0·30, 95% CI 0·23–0·39, 
p=0·0001). Biochemical relapse was the ﬁ rst reported 
evidence of relapse in 160 (46%) patients (119 in the ADT 
only group and 41 in the ADT and RT group), and local 
progression was the ﬁ rst reported type of relapse 
in 111 (32%) patients (97 in the ADT only group and 14 in 
the ADT and RT group). 58 patients in the ADT only 
group whose local disease progressed were given RT at 
the time of relapse.
Severe late side-eﬀ ects higher than grade 3 were 
uncommon in both groups (table 2). As expected, grade 1 
and 2 gastrointestinal toxicity (manageable diarrhoea and 
rectal bleeding) increased in the ADT and RT group. 
Baseline HRQoL scores for the measures most relevant 
to prostate RT are shown in table 1. Compliance was high 
at baseline (1031 patients, 89%) and was still high for 
both EORTC and FACT-P at 36 months (>86% at all time 
points). Table 2 shows the mean change in scores for 
measures relevant to prostate RT at 6 months and 
36 months. Similar to toxicity scores, genitourinary-
speciﬁ c measures were high at baseline (presumably 
because of disease-related symptoms). Gastrointestinal-
speciﬁ c measures were captured only by the EORTC 
PR-13, revealing short-term (6 month) but not long-term 
(36 month) diﬀ erences between groups. Figure 3 shows 
the mean scores over time for symptom measures, 
indicating the between-group diﬀ erences in symptoms 
and early overall quality of life (EORTC). Overall quality 
of life and physical function scores show a general 
deterioration of physical function in both groups, 
consistent with ADT suppression (webappendix p 1).
The interim analysis only addressed survival, toxicity, 
and quality of life, therefore the analysis of the rates of 
surgical intervention was deferred until the ﬁ nal analysis, 
when more data would be available.
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Figure 3: Mean quality-of-life scores over time for symptom measures. 
A high mean score represents a high symptom burden. ADT=androgen deprivation therapy. EORTC=European Organisation for Research and Treatment of Cancer. 
FACT-P=Functional Assessment of Cancer Therapy–Prostate.
See Online for webappendix
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Discussion
This trial shows a greater beneﬁ t of combined modality 
therapy—RT and ADT—than of treatment with ADT 
alone in the management of patients with locally advanced 
prostate cancer. Combined modality treatment resulted in 
a reduction in overall mortality and disease-speciﬁ c 
mortality. The addition of RT also reduced disease 
progression and the rate at which local disease progression 
presented. The side-eﬀ ects of RT were modest clinically, 
and the frequency of serious toxicity was low.
As in this study, the SPCG-7 study14 showed an improved 
outcome with the addition of RT to hormonal therapy in 
patients with non-metastatic prostate cancer (panel). 
Although both studies addressed the issue of eﬀ ect of RT 
on survival, important diﬀ erences between them exist; 
patients in the SPCG-7 trial had a more favourable 
prognosis than patients in this study. In the SPCG-7 trial 
20% of patients had intermediate-risk disease, the 
maximum allowable PSA concentration was 70 ng/mL, 
patients with PSA concentrations higher than 11 ng/mL 
were surgically staged, and those with positive pelvic 
nodes were excluded from the trial. By contrast, in our 
trial, patients had much more advanced disease—all 
were high-risk and fewer than 5% had their pelvic nodes 
surgically assessed. The two trials also had some 
diﬀ erences in the treatment. In the SPCG-7 study, total 
androgen blockade was given for the ﬁ rst 3 months, then 
antiandrogen monotherapy until progression or death; 
in our study, hormonal treatments were continuous 
LHRH analogue or bilateral orchiectomy. The use of 
antiandrogen monotherapy would not be judged an 
adequate ADT by modern standards. Additionally, the 
pelvic lymph nodes were not treated with RT in the 
SPCG-7 trial, by contrast with our study.
With a median follow-up of 6 years, serious long-term 
genitourinary or gastrointestinal toxicity from RT was 
uncommon. These ﬁ ndings are supported by patient-
reported outcomes, which show that the negative eﬀ ect of 
RT on bowel function was modest clinically, with recovery 
of scores by 36 months tending to match those who did 
not have RT. These results are consistent with temporary 
RT toxicity and suggest that concerns about the side-
eﬀ ects of RT are not a reason to withhold treatment. As 
expected for patients receiving ADT, a decrease in global 
and physical function was evident in both groups. Neither 
the recorded conventional toxicity data nor the patient-
reported HRQoL data show between-group diﬀ erences in 
long-term genitourinary toxicity, although the FACT-P 
scores do show a small increase in genitourinary symptom 
scores at 6 months in patients receiving RT.
Our trial used continuous ADT, which is consistent with 
the prevailing view in the early 1990s of duration of 
therapy. However, although the optimum duration of ADT 
in locally advanced disease still needs to be deﬁ ned, all 
available data suggest that long-term use is associated with 
an improved outcome.17,18 The long-term morbidity and 
possibly mortality of ADT should be included in the risk–
beneﬁ t ratio when considering long-term combined 
modality treatment. Loss of bone density, increased 
fragility fractures, problems with cognition, increased risk 
of diabetes, and increased cardiac morbidity and mortality 
with ADT have been reported in addition to fatigue, hot 
ﬂ ushes, decreased libido, and erectile dysfunction.19–22
Although our study and interim analysis have 
strengths—randomisation and a large sample size—we 
note some limitations. Cause of death was assessed by 
the local investigator and some bias could have been 
introduced into the disease-speciﬁ c survival endpoint 
because the treatment allocation was not masked. 
Another limitation was that data for skeletal adverse 
events were not obtained—at the time of the study’s 
inception the importance of bone health in patients 
treated with ADT was not appreciated. Data for 
cardiovascular complications of ADT were obtained but 
not analysed in this interim analysis; however, they will 
be published in the ﬁ nal study report. The criteria for 
PSA concentration progression were those used in 
the original protocol designed in 1993—biochemical 
progression results obtained with the Phoenix–ASTRO 
criteria23 will be reported in the ﬁ nal analysis.
In our ﬁ nal analysis we intend to calculate 
multivariable risk scores for all patients to verify that 
risk is much the same between the two treatment 
Panel: Research in context
Systematic review
Whether the addition of radiation therapy improves overall 
survival in men with locally advanced prostate cancer receiving 
androgen deprivation therapy is unclear. We searched PubMed 
for phase 3 trials, guidelines, meta-analyses, randomised 
controlled trials, and reviews, using the MeSH terms “prostatic 
neoplasms“, “radiotherapy“, and “hormonal therapy“. The 
search was restricted to reports published in English up to 
April 18, 2011. Additional papers identiﬁ ed by PW and MM 
were also included. We identiﬁ ed two randomised trials that 
have addressed this issue and had conﬂ icting results—one 
showed improved survival (a large study of a favourable subset 
of patients with locally advanced disease) and the other (a 
small underpowered trial) showed no change in survival.5,14
Interpretation
In our randomised study with an unselected cohort of 
1205 patients the addition of radiation therapy to androgen 
deprivation therapy improved overall survival. This trial 
was the ﬁ rst study powered to assess the eﬀ ect of 
androgen-deprivation therapy and radiotherapy on overall 
survival compared with androgen deprivation therapy alone 
in a locally advanced prostate cancer (with eligibility not 
restricted on the basis of prognostic factors). No clinically 
important adverse eﬀ ects on late treatment toxicity were 
recorded. This trial provides convincing evidence that local 
control of disease in the prostate improves survival in 
patients with locally advanced prostate cancer.
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groups. We will also do an exploratory analysis to test 
whether any diﬀ erence in outcomes exist when patients 
are stratiﬁ ed by baseline level of risk. The dose of RT 
used in this trial (65–69 Gy) is low by modern standards. 
However, this dose was the standard of care in the 1990s 
when the trial was started. In the past 15 years the 
development of new RT tech niques has allowed for a 
20–25% increase in RT dose while keeping an acceptable 
morbidity in patients who would have been eligible for 
this trial. Randomised trials of dose escalation in low-
to-intermediate risk patients, treated with and without 
ADT, have shown improved local control and freedom 
from recurrence with minimum toxicity, and 
furthermore, the improvement in survival with the 
addition of RT to ADT recorded in this trial could be 
increased again with modern RT dose fractionation 
schemes.24,25 In our study, elective treatment of the 
pelvic lymph nodes was done in most cases but the 
possible beneﬁ t of this approach is still controversial.26 
Future analyses will explore the relation between the 
use of pelvic nodal radiation and disease-related 
outcomes in the study population. However, such data 
can apply only to outcomes from the modest doses of 
pelvic nodal irradiation that we delivered in the time 
before intensity-modulated RT (IMRT) became 
available. Higher doses can be safely delivered with 
IMRT than with previous techniques, and the 
continuing random ised trials re-examining pelvic nodal 
radiation and disease-related outcomes are the only way 
to address this issue with current technology.
That clinicians’ and patients’ preferences have an 
important role in the selection of treatment for patients 
with locally advanced prostate cancer is not surprising in 
view of the absence of good quality evidence of the 
eﬀ ectiveness of alternative treatment approaches. This 
lack of evidence is shown in the wide variation in current 
practice patterns, with noticeable geographic diﬀ erences 
in the use of curative treatment approaches. Furthermore, 
the use of ADT alone as primary management has 
increased in the past 20 years, a practice not supported by 
the results of our trial.27
Our ﬁ ndings suggest that the beneﬁ ts of the 
combination of ADT and RT should be discussed with all 
patients considering a curative treatment approach.
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